Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies

Developing innovative immunotherapies for cancer and infectious diseases

Developing innovative immunotherapies for cancer and infectious diseases

Copyright 2022 Abound Bio, Inc.      Terms      Privacy Policy

Kurt Gehlsen

Consultant, Strategic and Business Development

Highly experienced senior executive with 30+ year’s experience in private and public companies, company formation and growth, technology and company investments, pharmaceutical and medical device product development, basic research, clinical development, regulatory affairs, strategic planning, business development, licensing, project management, investor relations and executive management.